CEO Message

BioComo is a biotech company founded in May 2008, developing cutting-edge technology platforms for creating the novel and predominant vaccine carriers and adjuvants to enhance immunity in collaboration with Microbiology and Molecular Genetics Department of Mie University. We have already succeeded in development of the highly efficacious and state-of-the art vaccine carrier and novel adjuvant candidates. Our technology will be applied to production of the next generation vaccines for the prevention of such infections as RS virus, Ebola virus and Influenza virus. It will also enable faster and cost-effective production of those vaccines. BC-PIV is our core platform technology which was named after our corporate name, BioComo and our leading vaccine carrier is derived from the recombinant human parainfluenza virus 2 (hPIV2) vectors. BioComo is dedicated to inventing “new vaccines Efor both global infection threats as well as malignant tumors. Our mission is to incubate the technology and the products to the stage allowing research collaboration for future commercialization and to help the innovation for people to live longer and healthier.

Masayuki Fukumura, Ph.D.
CEO and President

署吁E width=

Corporate Profile

NameBioComo Incorporation
FoundationMay 30 2008
Head Office1325 Komono, Komono-cho, Mie-gun, Mie, 510-1233,
Biocomo Main Office at Mie University Campus319, 2-174 Edobashi, Tsu city, Mie, Japan
Executive Member Masayuki Fukumura, Ph.D., Founder, CEO & President Mitsuhiro Fujita, Board, CFO
Hiroki Hideshima, Board
Hiromu Ozaki, Board
Mission BioComo is a research and development-based biotech company founded in 2008 and dedicated to bringing innovative technology to human health. Our primary aim is to save sufferers by the infectious diseases or malignant tumors through two technology platforms, vorosome and recombinant viral vector technologies.
Contact Phone/Fax: +81-59-392-7333


Access to Biocomo Main Office at Mie University Campus
University Campus Incubator Building
Room 319

Page Top